PMC:7755033 / 18933-19264 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T161","span":{"begin":52,"end":58},"obj":"Sentence"},{"id":"T162","span":{"begin":60,"end":72},"obj":"Sentence"},{"id":"T163","span":{"begin":73,"end":231},"obj":"Sentence"},{"id":"T164","span":{"begin":233,"end":239},"obj":"Sentence"},{"id":"T165","span":{"begin":241,"end":250},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"experimentation (Ghose, 1987; Ghose et al., 1999).\n\n2.2.4. Leadlikeness\nAccording to Teague et al. (1999) compounds with MW in the range 250–350, a XLOGP3 value of \u003c3.5 and \u003c7 rotatable bonds satisfy the criteria for leadlikeness.\n\n2.2.5. Egan rule\nIt is defined as compounds having TPSA \u003e 131.6 Å or log p \u003e 5.88 have drug-like "}